

Neovii, Mundipharma enter strategic collaboration

July 6, 2018 | News

Grafalon is the recognised standard of care in leading transplant centres.



Neovii pharmaceuticals AG of Rapperswil, Switzerland and Mundipharma have entered into an agreement giving Mundipharma the rights to develop and distribute its polyclonal antibody immunosuppressant Grafalon, in China and Japan from end October.

Grafalon is indicated in solid organ transplant for prevention and treatment of acute rejection, graft-vs-host disease (GvHD) in stem cell transplant (SCT) and in the treatment of aplastic anemia. Grafalon is the recognised standard of care in leading transplant centres.

Under its license, Mundipharma intends to strengthen the distribution and support of Grafalon in these key markets to advance the clinical development for the prevention of chronic GvHD in SCT.

Grafalon is currently approved for prevention of rejection and the treatment of acute steroid resistant rejection in solid organ transplant in China.